Seattle’s biotech sphere just got that little bit larger. Thanks partly to Amazon’s Jeff Bezos, Nautilus heads into Q2 of 2021 with an additional financial boost. But how will this help the venture with future projects and growth? How can other startups gain inspiration?
Who is Nautilus?
Nautilus is a biotechnology venture with roots in proteome research. This substance is a type of protein that the company’s team is keen to study to help enhance existing research. What’s more, Nautilus has designs on helping to improve predictive medicine.
It’s a company headed by Sujal Patel, who was previously co-founder at Isilon. Professor Parag Mallick, too, is on board as a co-founder since its inception in 2016.
Nautilus advises that the majority of FDA-approved medicine is protein-centric. The brand also confirms that there is little growth in R&D despite increasing expenditure year on year. Nautilus, therefore, has roots in looking into protein sensitivity.
Ultimately, like many startups in the biotech sphere, Nautilus is looking for a breakthrough of sorts. A revolution in protein research could help medicine developers find new ways to ensure drugs are more cost-effective.
How Will Financing Help the Firm?
Of course, Amazon’s Jeff Bezos’ funding will help Nautilus develop further products and set out a more precise roadmap. Recent news also states that a $350 million deal will help improve its analysis services via special purpose acquisition.
The SPAC deal will bring in $200 million from current backers and unveil $150 million from the Arya Sciences Acquisition Corp III. Currently, SPACs are thought to help raise more than $73 billion for growing ventures.
Nautilus, thanks to its high-profile backing, offers a public value of $900 million. It receives support from the likes of Perceptive, an investment body specializing in biotech. In time, GeekWire estimates that Nautilus may be worth as much as $1.3 billion. This is following public equity offering and the SPAC rounds.
Ultimately, companies such as Nautilus require investments to fund human hours and advancing technology. The research Patel and Mallick’s team wishes to undertake will take considerable time and engineering effort to bring forward. Its hardware and software-driven service will seek to make significant changes in the world of therapeutic medicine.
What Can Startups Learn?
Nautilus is one of several biotech innovators with the ‘it’ factor big investors are looking for. While most ventures will seek to change the world in one way or another, Nautilus has an edge. This edge is a clear track record and a self-described revolutionary platform.
For other firms in the biotech sphere, Nautilus’ story will likely be inspirational. The potential for human and medicinal R&D is truly unlimited. What will the company unearth in years to come?
Biotech startups are emerging not only from Seattle but all over the US. Investors keen to tap into the future of medicine may wish to use startup databases such as Fundz to break through. Could the answer to everyday maladies be just around the corner?